Podcasts about diagnostics

What if your biggest marketing obstacle isn't bad data, but the wrong diagnosis? In this episode of StrategyCast, learn how rigorous diagnostics fuel smarter strategies, why true differentiation matters, and how brand and performance marketing can win, together!And don't forget! You can crush your marketing strategy with just a few minutes a week by signing up for the StrategyCast Newsletter. You'll receive weekly bursts of marketing tips, clips, resources, and a whole lot more. Visit https://strategycast.com/ for more details.==Let's Break It Down==06:20 Opportunity Assessment Limitations10:20 "Marketing Insights at Pepper & Hershey"12:07 Bringing Consumer Insight to Operations17:25 "Strategic Differentiation for Brand Growth"19:55 "Diagnostics to Strategy: Making Choices"24:41 Assessing Strategic Opportunities26:59 Brand Stretching Limits: Arm & Hammer31:55 Integrated Marketing Key to Success34:49 Ad Tech Mistakes and ROI Challenges37:24 Marketing Basics: Broad, Inclusive Reach==Where You Can Find Us==Website: https://strategycast.com/Instagram: https://www.instagram.com/strategy_cast/Facebook: https://www.facebook.com/strategycast==Leave a Review==Hey there, StrategyCast fans!If you've found our tips and tricks on marketing strategies helpful in growing your business, we'd be thrilled if you could take a moment to leave us a review on Apple Podcasts. Your feedback not only supports us but also helps others discover how they can elevate their business game!

Sales legend and trainer Steve Gielda—co-founder of Ignite Selling—joins Samuel to break down what truly drives performance in medical device, pharma, biotech, and diagnostics. Steve traces his path from selling 3M copiers out of a van to leading life-sciences consulting with Neil Rackham (of SPIN Selling) and building Ignite's simulation-based, gamified training that accelerates pipelines and product launches. We get tactical fast: how today's top reps think strategically, map real stakeholders (beyond the “friendly” contacts), and use smarter questions that challenge clinical and business assumptions—not just needs. Steve explains when SPIN still shines, where Challenger-style questions raise the bar, and why role-playing strategy is as critical as role-playing the call. For frontline managers, Steve lays out the playbook: coach early in the pipeline, ask more than you tell, know when to sell vs. when to coach, and—yes—let your reps fail on safe calls so they learn to win without you. We dive into work ethic vs. knowledge, turning average reps into top performers, and the signals that a high producer is (or isn't) ready for leadership. If you want practical frameworks to sharpen your questioning, focus your account strategy, and elevate your team's coaching culture, this episode delivers candid insights you can apply on your very next call. Connect with Steve: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

Peter Maurer, Assistant Professor of Molecular Engineering at the University of Chicago Pritzker School of Molecular Engineering, speaks with Pitt's HexAI podcast host, JordanGass-Pooré, about the future impact of quantum sensing on biomedical research and diagnostics.Peter's research lab leverages the extreme environmental sensitivity of quantum systems to develop powerful sensors suitable for cutting-edge biological research that are optically addressable and can operate under ambient conditions. He outlines both near-term and future applications of powerful quantum sensors in pathology and laboratory medicine. He provides a key example of how these sensors could enable a new type of nanoscale NMR spectroscopy, capable of measuring magnetic fields from biomolecules to non-invasively probe their chemical information and signaling pathways. In the near future, he points to diagnostic tools, currently being developed by companies, that use the unique optical signatures of quantum sensors for highly sensitive, background-free protein detection in small volumes. For the long term, he envisions the technology as a "field opener" for studying protein aggregation in neurodegenerative diseases like Alzheimer's and Parkinson's.Peter outlines how AI can be applied to analyze complex data from sensors that respond to multiple environmental factors and highlights the challenge of bringing together experts from quantum technology, biophysics, and medicine who can "talk each other's language.” He also touches on how the use of synthetic data in quantum sensing is a "completely under-appreciated" area with the potential to analyze complex environmental properties that would otherwise be missed by looking at single types of measurements. To advance the field from academic proofs-of-concept to clinical tools, he stresses the need for collaboration with academic and industry partners who can help engineer robust, "turnkey" systems that can be widely tested and used.The University of Pittsburgh Health and Explainable AI podcast is a collaborative initiative between the Health and Explainable AI (HexAI) Research Laboratory in the Department of Health Information Management at the School of Health and Rehabilitation Sciences, and the Computational Pathology and AI Center of Excellence (CPACE), at the University of Pittsburgh School of Medicine.Hosted by Jordan Gass-Pooré, a health and science reporter, this podcast series explores the transformative integration of responsible and explainable artificial intelligence into health informatics, clinical decision-making, and computational medicine. From reshaping diagnostic accuracy to enhancing patient care pathways, we'll highlight how AI is creating new bridges between researchers, clinicians, and healthcare innovators. Led by Ahmad P. Tafti, Hooman Rashidi and Liron Pantanowitz, the HexAI podcast is committed to democratizing knowledge around ethical, explainable, and clinically relevant AI. Through insightful conversations with domain experts, AI practitioners and students will spotlight the latest breakthroughs, discuss real-world applications, and unpack the challenges and opportunities that lie ahead in responsible AI in healthcare. So whether you're a student, practitioner, researcher, or policymaker, this is your gateway to the future of AI-powered healthcare

Lauren Rosenberg, a highly experienced Physician Associate, has dedicated nearly two decades to Internal Medicine and Health Optimization. Driven by a passion for preventative care, Lauren founded Vent Health to shift the focus from disease treatment to prevention. She specializes in a personalized approach that blends genetics, epigenetics, biomarkers, and lifestyle factors to tailor health interventions that extend and optimize each patient's healthspan. Lauren's practice includes prescribing peptides (GLP, CLP/GIP) for weight loss, insulin resistance, pre-diabetes, etc.  This episode concentrates on MENOPAUSE. Lauren and Heather discuss what symptoms could be related to Menopause.  Lauren will speak about hot flashes, heart palpitations, frozen shoulder, brain fog, lack of libido, itchy ears, anxiety, trouble sleeping, hair changes, urinary tract infections. They will discuss what can you do at home and what treatments can be beneficial from professionals, such as GLP 1's for weight gain and  hormone replacement options.  Lauren is a frequent speaker at the Age Management Medicine Group (AMMG) and the American Academy of Anti-Aging Medicine (A4M) conferences.  Lauren's practice includes Cardiology prevention: Diagnostics and AI analysis to detect dangerous plaque and calcium; advanced lipid testing and cardiovascular genetics Longevity biomarkers: DNA methylation for biological age, VO2 max testing, Telomere health; Therapeutic plasma exchange Cancer prevention: methylated DNA screens, preventative MRIs, tumor marker testing.  Lauren's Website:     https://myventhealth.com/about/ Heather's Website: www.heatherthomson.com Social Media: IG: https://www.instagram.com/iamheathert/                     You Tube: https://youtube.com/@iamheathert?si=ZvI9l0bhLfTR-qdo SPONSORS:  BLISSY: Blissy is offering 60-nights risk-free PLUS an additional 30% off when you shop at www.Blissy.com/HEATHERPOD and use code HEATHERPOD. Your hair and skin will thank you! AIRDOCTOR: Go to AirDoctorPro.com and use promo code HEATHER to get UP TO $300 off today! AirDoctor comes with a 30-day money back guarantee, plus a 3-year warranty—an $84 value, free! Get this exclusive, podcast-only offer now at www.AirDoctorPro.com using promo code HEATHER. Learn more about your ad choices. Visit megaphone.fm/adchoices

Send us a textLast month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, initially developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy conversation, but one key point is that screening a mass population for HCC or cirrhosis has an entirely different set of issues and criteria compared to the screening usually discussed on this podcast, which involves identifying a population at increased risk for MASLD or MASH and screening them. Also, healthcare is far more expensive than it was in 1960 with a plethora of high-cost ways to diagnose, treat and manage patients.As a result, the authors started with the 10 Wilson and Jungner criteria and added eight more. During this conversation, Stine emphasizes the need for a comprehensive clinical trial on this issue, and all panelists agree that LiverAIM is likely to serve as the study.

Send us a textThis discussion on ways to improve MASH patient management comes from the early July roundtable on "Major Issues of the First Six Months of 2025." As a reminder, that roundtable included the three co-hosts (Louise, Jörn Schattenberg and Roger Green) Louise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. The discussion also extends to the role of NITs in diagnosis and patient management, and how providers need to shift the paradigm away from describing a patient by fibrosis stage and instead focus on the amount of fat in the liver and its overall suppleness.

Send us a textLet me begin by asking you: Have you ever sat in a dentist's chair, nervous, wishing the pain would end quickly? Now imagine instead of long drills and endless appointments, advanced robots and artificial intelligence tools handle procedures with incredible speed and accuracy. Sounds like a scene from a sci-fi movie, right? But let me tell you, this is already happening.Connect With Kapeel Guptaor Click on the link: http://bit.ly/4jlql8sWhat You May Learn00:00 Introduction02:05 Mission Statement02:25 #1: AI and Robotics Landscape in Modern Dentistry03:49 #2: AI powered Diagnostics & Personalised Treatment Planning05:06 #3: Robotics Automation in Clinical Procedures06:28 #4: Upskilling for the Future : Career Pathways & Training08:03 #5: Ethics, Regulation & Building Patient Trust09:20 Conclusion10:13 Call to actionSupport the show

Alexion recently launched the second film in its Rare Connections series, Rare Connections in gMG.Managing editor Jack O'Brien talks with Lucid Diagnostics' chief technology and compliance officer Dr. Brian deGuzman about the company's nationwide initiative to provide education and testing for esophageal precancer.He explains how the NFLPA factors into the effort, which launched in Cincinnati, and how it is expanding across the country to address the heightened risk these athletes have for developing esophageal pre-cancer.Check us out at: mmm-online.com  Fast Break theme music: Mark Buergler - On The Run, Triple Scoop Music Step into the future of health media at the MM+M Media Summit on October 30th, 2025 live in NYC! Join top voices in pharma marketing for a full day of forward-thinking discussions on AI, streaming, retail media, and more. Explore the latest in omnichannel strategy, personalization, media trust, and data privacy—all under one roof. Don't wait—use promo code PODCAST for $100 off your individual ticket. Click here to register! AI Deciphered is back—live in New York City this November 13th.Join leaders from brands, agencies, and platforms for a future-focused conversation on how AI is transforming media, marketing, and the retail experience. Ready to future-proof your strategy? Secure your spot now at aidecipheredsummit.com. Use code POD at check out for $100 your ticket! Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music.

Send us a text00:00:00 - Surf's Up: Season 6 Episode 13 Louise Campbell, Jörn Schattenberg and Roger Green continue their discussion of some major issues from earlier this year, while co-authors Aleksander Krag and Stine Johanset join Roger to discuss their recent publication in The Lancet, titled "Screening for Advanced Liver Disease." 00:04:45 - Major Issues of the First Six Months: Integrated Patient ManagementLouise drives this conversation based on two related issues she sees emerging: (i) increasing opportunities for motivated patients to manage their own health and (ii) managing the total patient in an environment where people may be taking incretin agonists as if they are consumer drugs. With increased access to scanning, providers can monitor patients (and patients can self-monitor) more closely. However, some of the issues a provider might find are tricky: patients who undertake what Louise describes as "the sneaky areas patients think are normal, but are probably contributing to disease" due to miseducation or no education on healthy eating and lifestyle, or patients purchasing and using incretin agonists through consumer channels, but possibly at subtherapeutic doses. Vigilance and probing are key here, but health systems will need to train more people on the types of probing that uncover underlying issues and behaviors that patients mistakenly believe to be healthy. 00:21:02 - Newsmakers: Aleksander Krag and Stine Johansen discuss Screening for Advanced Liver DiseaseLast month, The Lancet posted online an article from Stine Johansen, Fredrik Åberg, Emmanuel Tsochatzis and Aleksander Krag, titled "Screening for Advanced Liver Disease." The article aims to update the Wilson and Jungner criteria, originally developed in 1960, to address modern needs and issues. In this conversation, Professor Krag and Dr. Johansen join Roger Green to discuss their article. There are many nuances and high points to cover in this thoughtful, fairly lengthy conversation, but the key point is that screening a mass population for HCC or cirrhosis has an entirely different set of issues and criteria compared to the screening usually discussed on this podcast, which involves identifying a population at increased risk for MASLD or MASH and screening them. 00:54:42 - Major Issues of the First Six Months: Changes in US Health Policy and Potential for Dynamism in the In-Office Scanning Market Roger drives this conversation, focusing on two very different, yet very important issues: the first is the increasing dynamism of the in-office scanning market, with leader Echosens developing new products and services, while companies like e-Scopics, Sonic Incytes, and Mindray (Hepatus) are introducing new devices with competing profiles. Roger discusses the idea that some scanners keep all data resident in the machine, while others send it immediately to the cloud. Louise suggests that we should welcome any reliable scanning device to the market. Separately, he lists some concerns about how the Trump Administration's focus on cutting services to the poor, coupled with Robert F. Kennedy Jr.'s distrust of pharmaceuticals and mainstream health research, might limit the number of Americans with access to healthcare and the kinds of care they can access. At the end of this conversation, Roger asks Jörn and Louise what they consider major issues for the next six months.01:11:40 - Business Report and Wrap-Up

This episode features Dr. Christopher Garcia, Chief Digital Innovation Officer at Mayo Clinic Laboratories, discussing how AI and big data are reshaping diagnostics. He shares insights on democratizing expertise, balancing innovation with patient safety, and creating trusted AI tools to advance healthcare.This episode is sponsored by Mayo Clinic Laboratories.

APMA in 2025 hosted "The National" at the Gaylord in Dallas, TX!   Dean's Chat, once again, went, "On Location"! This episode is sponsored by Bako Diagnostics, that graciously shared their booth with Dean's Chat! Dr. Johanna Richey interviewed many attendees discussing the scientific meeting, the networking, the collaboration and comaraderie withing the podiatric community.  Tune in for short interviews, this Part 2 episode consists of interviews on July 16, 2025.  Enjoy!  It was an incredible meeting for all!

We break down pneumothorax: risks, diagnosis, and management pearls. Hosts: Christopher Pham, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Pneumothorax.mp3 Download Leave a Comment Tags: Chest Trauma, Pulmonary, Trauma Show Notes Risk Factors for Pneumothorax Secondary pneumothorax Trauma: rib fractures, blunt chest trauma (as in the case). Iatrogenic: central line placement, thoracentesis, pleural procedures. Primary spontaneous pneumothorax Young, tall, thin males (10–30 years). Connective tissue disorders: Marfan, Ehlers-Danlos. Underlying lung disease: COPD with bullae, interstitial lung disease, CF, TB, malignancy. Technically, anyone is at risk. Symptoms & Differential Diagnosis Typical PTX presentation: Dyspnea, chest pain, pleuritic discomfort. Exam clues: unilateral decreased breath sounds, focal tenderness/crepitus. Red flags (suggest tension PTX): JVD Tracheal deviation Hypotension, shock physiology Severe tachycardia, hypoxia Differential diagnoses: Pulmonary: asthma, COPD, pneumonia, pulmonary edema (SCAPE), ILD, infections. Cardiac: ACS, CHF, pericarditis. PE and other acute causes of dyspnea. Diagnostics Bloodwork: limited role, except type & screen if intervention likely. EKG: reasonable given chest pain/shortness of breath.

Send us a textKey Opinion Leaders Manal Abdelmalek, Naim Alkhouri, Scott Isaacs and Zobair Younossi join Roger Green to discuss  FDA's approval of semaglutide for patients with non-cirrhotic MASH. This conversation focuses on benefits for patients and ways that having two drugs with different modes of action will change pharmacotherapy choices.This conversation starts with the group describing the sense of "enthusiasm" and "fulfillment" hepatology drug developers feel to see two drugs approved in the US and many other major changes to come (more drug approvals, FDA acceptance of a path to approval that is not based on liver biopsy). One interesting takeaway is that while the approval of semaglutide will likely change the number of patients treated with MASH pharmacotherapy, the greater impact of this approval will be on public awareness of MASH and the accompanying demand for treatment. In terms of actual drug use, the first major change will come among patients living with obesity but not Type 2 diabetes. Most of these patients previously saw their semaglutide prescriptions rejected for payment by health insurers. However, many of these patients will be living with MASH, and they are likely to see their prescriptions approved. Instead, the largest impact may involve increased education and awareness. Scott pointed out that endocrinologists, who frequently prescribe incretin agonists, will have reason to learn how to diagnose and manage MASH in patients they already treat. Zobair noted that an array of companies, starting with pharmaceutical manufacturers and scanning companies, will dramatically increase investments in prescriber and patient education. Another important benefit may come in terms of coverage. Scott points out that most patients living with obesity but not diabetes are unlikely to have their semaglutide prescriptions covered by commercial insurers. Those living with non-cirrhotic MASH are likely to have semaglutide covered. A separate but related point: Naim reports that ~30% of the MASH patients he sees are taking an incretin agonist at the time of initial visit.

Open AI et tous les projets qu’ils ont lancés cet été. Discussion IA avec David Proulx. Regardez aussi cette discussion en vidéo via https://www.qub.ca/videos ou en vous abonnant à QUB télé : https://www.tvaplus.ca/qub ou sur la chaîne YouTube QUB https://www.youtube.com/@qub_radioPour de l'information concernant l'utilisation de vos données personnelles - https://omnystudio.com/policies/listener/fr

Het Openbaar Ministerie (OM) heeft een strafrechtelijk onderzoek gestart naar de hack bij het laboratorium Clinical Diagnostics. Door de hack zijn de gegevens van bijna een half miljoen Nederlandse vrouwen gestolen, hoewel de dader beweert dat die weer verwijderd zijn. Niels Kooloos vertelt erover in deze Tech Update. Het onderzoek van het OM richt zich vooral op de personen die achter de verantwoordelijke hackersgroep Nova zitten. De politie zou digitale sporen gevonden hebben die mogelijk naar hun identiteiten kunnen leiden. Dat is twee weken geleden al gebeurd, maar vanwege 'het opsporingsbelang' heeft het OM dat nu pas bekend gemaakt. Tegelijkertijd melden steeds meer slachtoffers van de hack zich bij advocatenkantoren om een massaclaim tegen Clinical Diagnostics voor te bereiden. In totaal hebben 70 duizend vrouwen wiens gegevens zijn gelekt zich al gemeld. Omdat het OM zelf al onderzoek doet, hoeven vrouwen 'geen aangifte meer te doen' bij die organisatie. Verder in deze Tech Update: Door een nieuw lek in de software van Citrix zijn meer dan duizend Nederlandse computersystemen kwetsbaar See omnystudio.com/listener for privacy information.

APMA in 2025 hosted "The National" at the Gaylord in Dallas, TX!   Dean's Chat, once again, went, "On Location"!   This episode is sponsored by Bako Diagnostics, who graciously shared their booth with Dean's Chat! Dr. Johanna Richey interviewed many attendees discussing the scientific meeting, the networking, the collaboration and comaraderie withing the podiatric community.  Tune in for short interviews, Part 1 consists of interviews on July 15, 2025. Part 2, to be released next week, consists of interviews on July 16, 2025. Enjoy!  It was an incredible meeting for all!

Het ministerie van Volkgsgezondheid, Welzijn en Sport bekijkt of BSN-nummers verplicht gebruikt moeten blijven worden in de zorg. Dat zegt een woordvoerder tegen nieuwssite Nu.nl. Aanleiding voor die uitspraak is de hack bij Clinical Diagnostics, waarbij de gegevens van bijna een half miljoen Nederlanders zijn buitgemaakt. Niels Kooloos vertelt erover in deze Tech Update. Zorginstellingen zijn verplicht om BSN-nummers van patiënten op te vragen en om die te koppelen aan dossiers. Het gehackte laboratorium Clinical Diagnostics deed dat daarom ook. Voordat het ministerie besluit of dat nog wel moet, wordt er eerst gewacht op de uitkomst van het onderzoek naar Clinical Diagnostics. De groep achter de hack, Nova, heeft vrijdag al aangekondigd de gestolen gegevens - inclusief BSN-nummers - te verwijderen. Het is niet te bevestigen of dat ook echt gebeurd is. Sowieso hebben de gegevens van 53 duizend Nederlanders even online gestaan. Verder in deze Tech Update: Intel ziet het belang van de Amerikaanse overheid in het bedrijf als een risico voor de internationale business De Poolse consumentenwaakhond onderzoekt of Netflix de prijzen wel zonder expliciet akkoord van abonnees mag verhogen See omnystudio.com/listener for privacy information.

Leviticus 16:15-19  1 John 1:5-2:6

Hackersgroep Nova eist niet langer dat het gehackte lab Clinical Diagnostics ruim een miljoen euro aan bitcoins betaalt om te voorkomen dat de persoonsgegevens van honderdduizenden Nederlanders worden gelekt. In een bericht op de eigen site op het dark web schrijft Nova: 'Misschien vragen we niet meer om geld, maar om iets anders.' Niels Kooloos vertelt erover in deze Tech Update. Clinical Diagnostics had al eerder een onbekend bedrag aan losgeld betaald aan Nova, maar omdat de politie is betrokken bij de hack zou er volgens de hackersgroep een afspraak geschonden zijn. Daarom eiste Nova eerder deze week dat Clinical Diagnostics nogmaals betaald met tenminste 11 bitcoins. Cybersecurity-expert Pim Takkenberg van cyberbedrijf Northwave vermoedt dat Clinical Diagnostics sindsdien geen contact meer heeft opgenomen met Nova en dat de groep daarom uit wanhoop minder hoge eisen stelt. Tegelijkertijd beweert Nova in hetzelfde bericht dat er geen data van honderdduizenden, maar van miljoenen Nederlanders is buitgemaakt. Verder in deze Tech Update: Meta stopt met het werven van nieuw personeel voor de AI-tak van het bedrijf Googles AI-chatbot Gemini zou voor een gemiddelde vraag maar vijf druppels water en een paar seconden televisiekijken aan stroom verbruiken, maar experts trekken die claim in twijfel See omnystudio.com/listener for privacy information.

In this episode of Medsider Radio, we sat down withTracy MacNeal, President and CEO of Materna Medical. Materna is developing two devices addressing different aspects of pelvic health: Ellora, aimed at preventing childbirth injuries during delivery, and Milli, designed to treat vaginismus, a pelvic floor condition that makes intercourse painful or impossible.Tracy is a healthcare executive and engineer with over 25 years of experience in medical devices, digital health, and women's health, including six successful transactions. In addition to heading Materna, Tracy serves on the AdvaMed Board and leads its Women's Health Equity Initiative, and was previously President of Diagnostics and Digital Health at Ximedica.In this interview, Tracy shares how clinical data enabled Materna to bridge B2B and B2C channels, and why clarity of focus is essential when commercialization paths diverge. Tracy also outlines what it takes to build in undefined markets, from aligning KOLs to publishing foundational definitions, and offers a candid perspective on what investors really want: clear financial returns, backed by a founder they trust to deliver when things go sideways.Before we dive into the discussion, I wanted to mention a few things:First, if you're into learning from medical device and health technology founders and CEOs, and want to know when new interviews are live, head over to Medsider.com and sign up for our free newsletter.Second, if you want to peek behind the curtain of the world's most successful startups, you should consider a Medsider premium membership. You'll learn the strategies and tactics that founders and CEOs use to build and grow companies like Silk Road Medical, AliveCor, Shockwave Medical, and hundreds more!We recently introduced some fantastic additions exclusively for Medsider premium members, including playbooks, which are curated collections of our top Medsider interviews on key topics like capital fundraising and risk mitigation, and 3 packages that will help you make use of our database of 750+ life science investors more efficiently for your fundraise and help you discover your next medical device or health technology investor!In addition to the entire back catalog of Medsider interviews over the past decade, premium members also get a copy of every volume of Medsider Mentors at no additional cost, including the latest Medsider Mentors Volume VII. If you're interested, go to medsider.com/subscribe to learn more.Lastly, if you'd rather read than listen, here's a link to the full interview with Tracy MacNeal.

Send us a textThis week's expert interview is with Dr. Emily Andaya, Medical Director of the Cardiovascular Program at Major Health Partners of Shelbyville, IN. She joins Louise Campbell and Roger Green to discuss the American Heart Assocation's CKM initiative, why she believe it should be titled "CKLM" for liver, and how including liver in the CKM scoring system would make it stronger and provide a more robust tool to help improve patients' health. Emily begins by discussing her attendance at the American Society for Preventive Cardiology meeting in Boston the previous weekend, where Dr. Christos Montzoros presented a talk proposing that the liver's role in cardiovascular diseases is "equally critical" compared to the kidney and other multi-metabolic co-morbidities. Dr. Montzoros closed his talk by stating that the CKM syndrome description should be changed to CKLM to reflect the importance of the liver, and that the CKLM patient scoring and criteria should reflect this as well.Next, Emily describes the 0-to-4 scoring system that the CKM initiative has chosen to use and the recommendations that accompany the scoring system itself. The system does not neatly overlay the 4-point fibrosis scoring system or the NAS score, but Emily describes how these might be incorporated into the CKM score. The conversation shifts to focus on patient management. Since the original CKM paper was published in 2023, resmetirom had not yet been approved and the paper itself focused more on screening than on treatment. To Emily, adding the "L" to CKM would entail adding resmetirom to treatment protocols as appropriate, and also considering drug combinations that addressed liver disease. Louise takes this issue from the other side, suggesting that every time a provider prescribes a drug to a CKM patient, the potential for negative liver effects should be part of the selection process. Emily and Louise agree that providers and patients should take a holistic approach to therapy for these patients. One benefit: even if a patient has multiple organs affected by multi-metabolic challenges, the provider can educate the patient that there is a single target disease to treat instead of multiple different diseases. As Roger notes, treating 4-5 discrete diseases simultaneously sounds overwhelming, while treating one overarching disease sounds far more manageable.The conversation ends with a focus on whether we are correctly identifying high-risk cardiovascular patients in the current environment, and how this more holistic focus might improve patient screening and identification.

Send us a textMulti-Metabolic Week focuses on the idea that MASLD and MASH are elements in a systemic set of Multi-Metabolic issues. This conversation is the first of two looking at the concept of the "Multi-Metabolic Clinic," a clinic that treats the entire spectrum of multi-metabolic diseases. The core of this episode starts during the weekly groundbreaker exercise, during which our guests began to describe the path that brought them from single-disease specialization to the broader multi-metabolic practice.. Immediately after the groundbreakers, participants describe their clinics today, including patient population and principles underlying their approach to treatment. For Karen, the path started in a conventional gastrointestinal practice. A decade ago, she gained certification in obesity medicine. While treating patients for obesity, she came to appreciate the interplay of obesity, diabetes and the other manifestations of multi-metabolic disease. Eventually, she divided her practice and time so that she spent half her time in the GI practice and the other half creating Trajectory Health Partners, a practice focused on overall metabolic health.For Dr. López, the initial goal was to "re-educate the hypothalamic problem," which he saw as the root cause of obesity and from which all other metabolic issues came. He describes this as "the auto-destruction button" of patients' lives, leading to two causes of death: (1) insulin resistance and related cardiovascular problems, and (2) short-telomere cancers. The rest of this conversation focuses on the tests that the two clinics use to confirm MASLD or MASH and their approaches to treating multi-metabolic patients.

Send us a text00:00:00 - Surf's Up: Season 6, Episode 11 This week, we modify our usual episode structure to focus on multi-metabolic practices and constructs. The multi-metabolic practices covered this week are run by non-hepatologists who have chosen to focus on the liver in a broader cardiometabolic context. They include two practices discussed during a two-part roundtable, one run by US gastroenterologist Dr. Karen Jerome-Zapadka and the EDOM practice in Spain, run by endocrinologists. The expert interview is with Dr. Emily Andaya, an internist who helms a cardiometabolic practice in Indiana, US, that focuses on the liver. 00:14:23 - Roundtable Part I: Groundbreaker and introductionThe core of the episodes started during the weekly groundbreakers, as guests began to describe the path that brought them from single-disease specialization to the broader multi-metabolic practice.. Immediately after the groundbreakers, participants describe their clinics today, including patient population and principles underlying their approach to treatment.00:26:15 - Roundtable Part II: Tools they useGuided by Louise, the specialists discuss the devices they use to screen and stage patients and the drugs they use to treat them. One interesting item that emerges is that EDOM relies on a 0-to-4 disease severity classification, but it does not align point-by-point with the 4-point fibrosis scale common in MASH. 00:40:28 - Roundtable Part III: Training Providers in the ClinicsLouise starts this segment by asking the EDOM team how they train practitioners in their clinic. EDOM trains practitioners in nutrition and technologists in the proper use of scanning devices. Karen comments that one big issue in re-training involves the length of visits: 15 minutes for a typical GI visit vs. 60 minutes for an initial multi-metabolic session and 30 minutes for follow-ups. Along with this, the information gathering technique are different.00:50:57 - Roundtable Part IV: Patient Health and Wrap-upLouise asks participants whether and how they have measured the impact the multi-metabolic approach has on patients' health (profound in both cases) and whether they are seeing an increase in HCC. Karen sees a difference among her long-term patients, while EDOM refers patients before their fibrosis reaches cirrhosis stage. In the last part of the episode, panelists share perspectives on how their initial specialties fit with the broader multi-metabolic practice and the kinds of impact they can have on patients.01:12:50 - Expert: Dr. Emily Andaya discusses US initiatives in multi-metabolic healthThis week's expert is Dr. Emily Andaya, an Indiana (US)-based internist whose practice has expanded to take on a multi-metabolic focus. She begins by discussing her recent attendance at the American Society for Preventive Cardiology (SPC) meeting in Boston, where she heard a talk by Dr. Christos Montzoros, an endocrinologist and multi-metabolic advocate, who emphasized the importance of incorporating the liver into preventive cardiology's focus. Louise and Emily agree that cardiometabolic focus involves evaluating general, overall health, but Emily discusses how this might require a deeper or broader testing protocol for each target organ. Emily describes the 4-point CKM scale and Louise asks how fibrosis or NAS scoring, as deployed in the MASH CRN system, might be valuable here. This is a far-ranging conversation, but one special point of interest involves the psychological benefit of telling a patient they need to treat one (multi-metabolic) condition, instead of separate heart, kidney, endocrinological and liver conditions, which might feel far more overwhelming. 01:48:48 - ConclusionBecause Roger is on vacation, there is no business report this week.

Send us a textAI in Pathology: ML-Ops and the Future of DiagnosticsWhat if the most advanced AI models we're building today are doomed to die in the machine learning graveyard?

In this episode Ed Interviews Dr. Carrie Harmon of the University of Florida plant diagnostic center. They discuss plant diagnostics, how they have evolved over time and how the National Plant Diagnostic Network (NPDN) unites diagnosticians across the country. Additional Resources https://npdn.org/ https://apsjournals.apsnet.org/doi/full/10.1094/PHYTOFR-11-24-0123-FI https://pubmed.ncbi.nlm.nih.gov/34432509/ https://apsjournals.apsnet.org/doi/epdf/10.1094/PHP-08-20-0074-MR How to cite the podcast: Zaworski, E. (Host) Harmon, C. (Interviewee). S4:E29 (Podcast). Symp-tomb Check: Evolving Plant Disease Diagnostics. 8/13/25. In I See Dead Plants. Crop Protection Network. Transcript

We've been working through 2 Timothy on Sunday evenings. Last week I preached from 2 Timothy 3:6-9. It's a passage–like many in the pastoral epistles–that deals with false teaching. Paul warns against the folly of false teaching (and against the folly of falling for it).Which leads to the question: what is false teaching and how do we spot it?Obviously, there is no foolproof scheme for identifying false teaching. Biblical discernment takes years of prayer, preaching, and practice. But there are certain questions that may be help us sift the good from the bad. Here are 15 discernment diagnostic questions I suggested to my congregation.10. Does it promote an unmediated approach to spirituality? Mysticism, in its technical sense, can be defined as an approach to God apart from mediation. False spirituality tries to foster intimacy with God that does not go through the mediated revelation of Scripture and does not lead one to the mediation of Christ on the cross.11. Does the false teaching traffic in under-defined terms and slogans? Liberalism starts with an inattention to words. It is the triumph of orthodoxy to be careful with language.12. Does the teaching neglect the need for repentance? Beware the feel good invitation for everyone to come to the wide open arms. The coming of the Kingdom is not good news for sinners. It is good news for sinners who repent.13. Does the false teaching or teacher seem obsessed about one person, one doctrine, or one idea? An unsolicited exposé running into the hundreds of pages likely reveals more about the author than the subject.14. Does it result in an unbalanced presentation of the truth? True Christianity walks the tight rope between complementary biblical truths—truth and grace, Christ as God and man, salvation by faith alone and the necessity of the obedience of the Christian. It was usually the heretics who were guilty of resolving biblical tensions in ways that were too neat and tidy.15. Does the teaching fit with the Bible's story line of sin and salvation? How can a holy God dwell in the midst of an unholy people? If the teaching doesn't make sense as a plot line in that story, I'm suspicious.Mature Christians do not cast a critical eye on everyone and everything a hair's breadth different from them. But they are discerning, and they are careful. Guard your heart. Guard your home. Guard the good deposit.For more information about this group, please visit their website at reformationboise.com. Every weekday at 8:00am you can listen to The Gospel for Life on 94.1 The Voice in the Treasure Valley, Idaho, USA. If you have a question, comment, or even a topic suggestion for the Pastors, you can email them. Phone: (208) 991-3526E-mail: thegospelforlifeidaho@gmail.comPodcast website: https://941thevoice.com/podcasts/gospel-for-life/

We've been working through 2 Timothy on Sunday evenings. Last week I preached from 2 Timothy 3:6-9. It's a passage–like many in the pastoral epistles–that deals with false teaching. Paul warns against the folly of false teaching (and against the folly of falling for it).Which leads to the question: what is false teaching and how do we spot it?Obviously, there is no foolproof scheme for identifying false teaching. Biblical discernment takes years of prayer, preaching, and practice. But there are certain questions that may be help us sift the good from the bad. Here are 15 discernment diagnostic questions I suggested to my congregation.10. Does it promote an unmediated approach to spirituality? Mysticism, in its technical sense, can be defined as an approach to God apart from mediation. False spirituality tries to foster intimacy with God that does not go through the mediated revelation of Scripture and does not lead one to the mediation of Christ on the cross.11. Does the false teaching traffic in under-defined terms and slogans? Liberalism starts with an inattention to words. It is the triumph of orthodoxy to be careful with language.12. Does the teaching neglect the need for repentance? Beware the feel good invitation for everyone to come to the wide open arms. The coming of the Kingdom is not good news for sinners. It is good news for sinners who repent.13. Does the false teaching or teacher seem obsessed about one person, one doctrine, or one idea? An unsolicited exposé running into the hundreds of pages likely reveals more about the author than the subject.14. Does it result in an unbalanced presentation of the truth? True Christianity walks the tight rope between complementary biblical truths—truth and grace, Christ as God and man, salvation by faith alone and the necessity of the obedience of the Christian. It was usually the heretics who were guilty of resolving biblical tensions in ways that were too neat and tidy.15. Does the teaching fit with the Bible's story line of sin and salvation? How can a holy God dwell in the midst of an unholy people? If the teaching doesn't make sense as a plot line in that story, I'm suspicious.Mature Christians do not cast a critical eye on everyone and everything a hair's breadth different from them. But they are discerning, and they are careful. Guard your heart. Guard your home. Guard the good deposit.For more information about this group, please visit their website at reformationboise.com. Every weekday at 8:00am you can listen to The Gospel for Life on 94.1 The Voice in the Treasure Valley, Idaho, USA. If you have a question, comment, or even a topic suggestion for the Pastors, you can email them. Phone: (208) 991-3526E-mail: thegospelforlifeidaho@gmail.comPodcast website: https://941thevoice.com/podcasts/gospel-for-life/

Caris Life Sciences was founded in 2008 with a simple but powerful purpose – to realise the potential of precision medicine and help improve the lives of as many people as possible. In a post-ASCO pharmaphorum podcast, web editor Nicole Raleigh spoke with Eric Matthews, chief business officer at Caris Life Sciences, about advancing the frontier of cancer diagnostics and treatment with breakthroughs in AI-driven pathology, real-world clinico-genomic data, and more. These other ASCO 2025 and post-ASCO conversations can be found here. You can also listen to episode 198a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.

We've been working through 2 Timothy on Sunday evenings. Last week I preached from 2 Timothy 3:6-9. It's a passage–like many in the pastoral epistles–that deals with false teaching. Paul warns against the folly of false teaching (and against the folly of falling for it).Which leads to the question: what is false teaching and how do we spot it?Obviously, there is no foolproof scheme for identifying false teaching. Biblical discernment takes years of prayer, preaching, and practice. But there are certain questions that may be help us sift the good from the bad. Here are 15 discernment diagnostic questions I suggested to my congregation.7. Does the teaching involve secrets? This was the appeal of Gnosticism. It purported to lead the initiate into the realm of secret knowledge. This is what makes me nervous about Masons, Mormons, and even many fraternities and sororities. Unless national security is involved, be wary of groups that are held together by tightly held secrets. Books with “secret” in the title are usually suspect too (Lesslie Newbigin's The Open Secret being the exception that proves the rule).8. Does it rely on a cartoon view of God? False teaching tends to cast God as either as a autocratic strongman or a friendly face passing out beads at Woodstock? By contrast, the God of the Bible shines forth with (to use Jonathan Edwards' phrase) a host of diverse excellencies.9. Does the teaching use big themes to negate specific verses? We should always interpret Scripture with Scripture, but we must not allow amorphous themes like love or justice or grace to flatten the contours of Scripture.For more information about this group, please visit their website at reformationboise.com. Every weekday at 8:00am you can listen to The Gospel for Life on 94.1 The Voice in the Treasure Valley, Idaho, USA. If you have a question, comment, or even a topic suggestion for the Pastors, you can email them. Phone: (208) 991-3526E-mail: thegospelforlifeidaho@gmail.comPodcast website: https://941thevoice.com/podcasts/gospel-for-life/

Für unsere Jubiläumsfolge, die 100 ste Folge von KAP Podcast sind wir nach Graz gereist und treffen an der MedUni ein multidisziplinäres Forscher Team. Heute geht's um etwas, das viele gar nicht auf dem Schirm haben – aber lebenswichtig ist: Kalium und um eine revolutionäre und bahnbrechende Technologie. Mit dem Gründer Team von elyte diagnosics, Prof. Dr. Julia Mader, DI Dr. Andreas Fercher und DI Dr. Stefan Köstler, tauchen wir ein in die faszinierende Welt der Medizintechnik. Birgit Eller Krumm ist Kapitän dieser spannenden Folge. Links zur Folge: Homepage: www.elytediagnostics.com Prof. Dr. Julia Mader, Mitgründerin und Chief Medical Officer der elyte diagnostics GmbH, ist Professorin für Diabetestechnologie an der Medizinischen Universität Graz und stellvertretende Leiterin der Diabetesambulanz. Sie schloss ihr Studium an der Medizinischen Universität Graz ab, wo sie auch die Facharztausbildung in Innerer Medizin und Endokrinologie absolvierte. Sie leitet die Forschungseinheit für Diabetestechnologie an der Medizinischen Universität Graz und ist Vorstandsmitglied der Österreichischen Diabetesgesellschaft, Vorstandsmitglied der EASD und Vorsitzende des Schulungs- und Ausbildungsausschusses der EASD. DI Dr. Andreas Fercher, Mitgründer und CEO der elyte diagnostics GmbH, leitet dort ein multidisziplinäres Team, das sich auf die Entwicklung eines einzigartigen Diagnosesystems konzentriert, das Millionen von Patienten helfen soll. Seine Motivation wird von der Vision angetrieben, innovativ zu sein und neue Wege zu beschreiten – ein Ziel, das er im Laufe seiner Karriere konsequent verfolgt hat. Vor der Gründung von elyte diagnostics veröffentlichte Dr. Fercher während seiner Forschungstätigkeit am University College Cork, Irland, mehrere Artikel in hochrangigen Fachzeitschriften und hält zahlreiche Patente. Anschließend entwickelte er über ein Jahrzehnt lang optische Sensorsysteme für schwerkranke Patienten, bevor er als Produktionsleiter und später als Leiter des Verifizierungs- und Validierungsteams zur B. Braun Melsungen Gruppe wechselte. DI Dr. Stefan Köstler, CTO der elyte diagnostics GmbH, hat einen Master-Abschluss in Chemieingenieurwesen und einen Doktortitel in physikalischer Chemie. Anschließend widmete er sich der angewandten Forschung in den Bereichen Chemo- und Biosensorik, Mikrofluidik und Oberflächentechnologien. Bis 2016 leitete er die Forschungsgruppe „Sensoren und funktionelle Drucktechnologien“ am Institut MATERIALS der JOANNEUM RESEARCH. Seitdem widmet er sich der Produkt-entwicklung in der Diagnostik-branche. Er war in der F&E-Leitung der PAYER Medical GmbH tätig – einem Hersteller von Polymer-Verbrauchsmaterialien und Sensormodulen – und leitete das F&E-Team der Erba Technologies Austria GmbH, die zur Erba Mannheim Gruppe gehört, einem globalen Anbieter von In-vitro Labordiagnostik-lösungen. KAP unterstützen - Wenn ihr Sponsor von KAP Podcast werden wollt, ist es ganz einfach. Patreon werden und mit einem Betrag eurer Wahl unsere Arbeit unterstützen. Hier ist der Link dazu patreon.com/kap_podcast KAP Homepage: www.kapture.ch Instagram: @kap_kapture Foto credit: KAP

We've been working through 2 Timothy on Sunday evenings. Last week I preached from 2 Timothy 3:6-9. It's a passage–like many in the pastoral epistles–that deals with false teaching. Paul warns against the folly of false teaching (and against the folly of falling for it).Which leads to the question: what is false teaching and how do we spot it?Obviously, there is no foolproof scheme for identifying false teaching. Biblical discernment takes years of prayer, preaching, and practice. But there are certain questions that may be help us sift the good from the bad. Here are 15 discernment diagnostic questions I suggested to my congregation.5. Do angels or aliens or seed money play a major role in the teaching? Enough said.6. Does it feature prominently the word “code”? Bible Code, DaVinci Code, Omega Code. Just stay away.7. Does the teaching involve secrets? This was the appeal of Gnosticism. It purported to lead the initiate into the realm of secret knowledge. This is what makes me nervous about Masons, Mormons, and even many fraternities and sororities. Unless national security is involved, be wary of groups that are held together by tightly held secrets. Books with “secret” in the title are usually suspect too (Lesslie Newbigin's The Open Secret being the exception that proves the rule).For more information about this group, please visit their website at reformationboise.com. Every weekday at 8:00am you can listen to The Gospel for Life on 94.1 The Voice in the Treasure Valley, Idaho, USA. If you have a question, comment, or even a topic suggestion for the Pastors, you can email them. Phone: (208) 991-3526E-mail: thegospelforlifeidaho@gmail.comPodcast website: https://941thevoice.com/podcasts/gospel-for-life/

This week, Shawn Wilkie and Dr. Ivan Zak meet with Dr. Eve Hanks, the founder of MI:RNA Diagnostics to chat about her remarkable journey from clinical veterinary practice to becoming the CEO of a pioneering diagnostics company. Eve shares how her background in immunology led to the creation of an AI-powered platform that uses microRNA to detect disease earlier than ever before. You`ll discover how predictive diagnostics can improve clinical decision-making, reduce uncertainty, and support personalized care for both pets and production animals.   Learn more about MI:RNA Diagnostics. Dr. Hanks recommends “The Body Keeps the Score: Brain, Mind, and Body in the Healing of Trauma” by Bessel van der Kolk M.D.

We've been working through 2 Timothy on Sunday evenings. Last week I preached from 2 Timothy 3:6-9. It's a passage–like many in the pastoral epistles–that deals with false teaching. Paul warns against the folly of false teaching (and against the folly of falling for it).Which leads to the question: what is false teaching and how do we spot it?Obviously, there is no foolproof scheme for identifying false teaching. Biblical discernment takes years of prayer, preaching, and practice. But there are certain questions that may be help us sift the good from the bad. Here are 15 discernment diagnostic questions I suggested to my congregation.3. Does it involve trinkets or relics or holy water? Christianity entails some mystery, no magic.4. Does it involve prophetic words? Christians may define prophecy differently. I'm not thinking here of a word fitly spoken, or powerful preaching, or wise counsel. I'm talking about “the Lord told me” sort of communication that tell other people what to do and cannot be tested or sifted according to Scripture.For more information about this group, please visit their website at reformationboise.com. Every weekday at 8:00am you can listen to The Gospel for Life on 94.1 The Voice in the Treasure Valley, Idaho, USA. If you have a question, comment, or even a topic suggestion for the Pastors, you can email them. Phone: (208) 991-3526E-mail: thegospelforlifeidaho@gmail.comPodcast website: https://941thevoice.com/podcasts/gospel-for-life/

What happens when you combine a decade of science, a powerful entrepreneurial story, and two exponential waves—AI and digital biology?You get Geneoscopy.On the latest episode of The Scope Forward Show, I caught up with Dr. Erica Barnell—Co-founder and Chief Science Officer of Geneoscopy. If you don't know Erica yet, you should. She and her team just raised $112 million in a tough VC environment. Their lead assay, ColoSense, is now the first FDA-approved, RNA-based, non-invasive diagnostic test for colorectal cancer and advanced adenomas.But this conversation went far beyond funding and FDA milestones.We talked about:How AI has replaced costly bioinformatics layers and transformed their R&DHow patients are being guided through diagnostics via smart automation (text, email, even Uber Health)What's next in IBD precision diagnostics and biomarker innovationWhy AI is not “artificial” at all—and how to use it without fearWhy GI, like OB/GYN, is primed for disruptionThis wasn't just a company update—it was a glimpse into the future of our entire field.We're in a convergence era. Biology is becoming programmable. Intelligence is being digitized. And GI—if we lean in—has a front-row seat to reinvent itself.

Most of us dread the dentist—awkward chairs, painful pokes, rushed cleanings. But what if oral care could be completely reimagined?Dr. Jonathan Levine, world-renowned prosthodontist and founder of Smile House, joins Get Well Better to explain why your mouth may be the most overlooked key to whole-body health—and how dentistry is becoming more high-tech, holistic, and human-centered than ever.From porcelain veneers to “mouth mapping” and microbiome testing, Dr. Levine breaks down how oral health connects to inflammation, longevity, and even brain function. He and host Chloe Harrouche explore the four pillars of oral wellness, the link between gum disease and chronic illness, and why your toothbrush, toothpaste, and tongue scraper matter more than you think.They also dive into how Smile House is redefining the dental experience through digital smile design, 3D imaging, and collaborative care that treats the whole person—not just their teeth.This episode is sponsored by Smile House, founded by Dr. Jonathan Levine—America's leading oral health expert. Smile House is NYC's go-to wellness destination where dental and functional health come together to help you live a longer, healthier, and more vibrant life.Get $100 off your first treatment at smilehouse.co by mentioning The Lanby podcast or Chloe Harrouche.Not in NYC? DM ‘GUIDE' to @SmileHouseTribeca on Instagram for Dr. Levine's free Oral Wellness Home Care Guide—your daily blueprint for a healthier mouth and body.TIMESTAMPS:00:00 Entrepreneurial Journey in Dentistry02:47 Innovations in Oral Health and Prosthodontics05:25 The Concept of Mouth Mapping08:23 The Four Pillars of Dental Health11:22 Diagnostics and Comprehensive Assessments14:20 Daily Habits for Optimal Oral Health20:41 Oral Hygiene Essentials23:46 The Impact of Diet on Oral Health26:41 Understanding Host Response and Environmental Factors28:38 The Interconnection of Oral and Overall Health31:49 Transforming Patient Relationships in Healthcare35:07 Teeth Whitening: Myths and FactsSUBSCRIBE: Apple Podcasts: https://podcasts.apple.com/us/podcast/get-well-better Spotify: https://open.spotify.com/show/get-well-betterYouTube: Or search “Get Well Better by The Lanby” on your favorite podcast platform!VISIT THE LANBY: Explore membership and learn more about The Lanby's functional medicine approach: https://www.thelanby.comFOLLOW THE LANBY ON SOCIAL: Instagram: https://www.instagram.com/thelanby TikTok: https://www.tiktok.com/@thelanby LinkedIn: https://www.linkedin.com/company/thelanbySTAY IN THE KNOW: Subscribe to The Lanby newsletter for health tips, podcast drops, and expert insights: https://www.thelanby.com/newsletter

What is false teaching and how do we spot it? Kevin DeyoungObviously, there is no foolproof scheme for identifying false teaching. Biblical discernment takes years of prayer, preaching, and practice. But there are certain questions that may help us sift the good from the bad. Here are 15 discernment diagnostic questions I suggested to my congregation.For more information about this group, please visit their website at reformationboise.com. Every weekday at 8:00am you can listen to The Gospel for Life on 94.1 The Voice in the Treasure Valley, Idaho, USA. If you have a question, comment, or even a topic suggestion for the Pastors, you can email them. Phone: (208) 991-3526E-mail: thegospelforlifeidaho@gmail.comPodcast website: https://941thevoice.com/podcasts/gospel-for-life/

Welcome to the 19th episode of the 2025 season! Nicolle Ritchie, MSU Extension Field Crops Educator, will host Dr. Sarah Hughson, Insect/Arthropod Diagnostician with the MSU Plant and Pest Diagnostics, will discuss  .  Also, a weather update from Dr. Jeff Andresen . To learn more and register for the live event, check out the MSUE Virtual Breakfast page.

This podcast is brought to you by Lilly, member of the SNMMI Value Initiative Industry Alliance. Hosts Anupa Arora, MD and Anthony “Nino” Sireci, MD discuss a New Era in Alzheimer Diagnostics. This episode takes a focused look at high-impact topics shaping the future of Nuclear Medicine and Molecular Imaging, designed specifically for professionals driving value in the field. 

Dr. Ifedayo Adetifa is a pediatrician and tuberculosis expert who led the Nigerian Centre for Disease Control during the Covid-19 pandemic. A year ago, he became the CEO of FIND, the global alliance for diagnostics, a product development partnership based in Geneva. A major innovation gap was FIND's initial focus – and remains a pressing priority. And over time, the access gap has become much more conspicuous and urgent. A 2021 Lancet Commission and recent update have proven highly valuable. The sudden decline in U.S. financing is having impact, directly and indirectly, upon FIND, but its diversification of funders has provided a cushion. FIND engages directly with over 100 US-based businesses. AI provides an opportunity for closing gaps in diagnosis, when combined with digital tools. However, there is a serious risk of low-income countries being left behind in the AI transformation. And a risk that diagnostics fall off the priority list.

Send us a textThis conversation is the fourth and final segment of SurfingMASH's April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologist and key opinion leader Sven Francque. The discussion focuses on PPARs, genetic medicines, and other emerging drug classes while considering the idea that drug therapies can have an impact on the liver independent of their effect on fibrosis regression. It begins with Sven  discussing his experience as a lead investigator in clinical trials for the pan-PPAR agonist lanifibranor, whose Phase 3 trial is now fully recruited. Sven states that in addition to fibrosis regression, lanifibranor is likely to exhibit other pleiotropic effects, and notes that vascular changes start early in the fibrotic progression process. After Sven elaborates on these effects, Louise asks about the SCD-1 agent Aramchol. This leads to a discussion about the idea that over time, therapy will probably come to incorporate two separate modes of action, with one to treat the metabolic dysfunction and the other to treat specific effects in the liver or, as Jörn puts it, "combining weight-neutral and weight-reducing drugs." This evolves into a discussion of what Louise terms "personal-centric" medicine, or what patient advocate Mike Betel has previously described on SurfingMASH as "tailored medicine."The rest of the conversation predominantly lists other classes of drugs, "safe" mitochondrial uncouplers, genetic medicines, and others. Roger inquires about the FASN inhibitors, which are entering Phase 3 clinical trials. Jörn says that the data appears positive and unique. That said, he and Sven agree we need more data.Louise sounds the closing note for this roundtable by discussing our co-founder, Stephen Harrison, and the energy and enthusiasm he brought to the entire drug development process. The group agrees that Stephen's impact continues to be felt through the MASLD community, even as he is missed by us all.

In this episode of Skin Anarchy, host Dr. Ekta Yadav sits down with Irina Mazur, Chief Product and Marketing Officer at Revieve, to explore how AI is revolutionizing beauty—not just in products, but in personalized consumer experiences. With a background in mobile tech and digital health, Irina brings a deep understanding of how data can solve real-world problems—especially in an industry where personalization has become a buzzword.Revieve is building something different: a diagnostic platform that uses selfie-based analysis and hundreds of proprietary skin metrics to provide tailored skincare, makeup, and wellness recommendations—without collecting any personally identifiable data. But this isn't just about tech. It's about helping people understand the truth about their skin, bridging the gap between perception and clinical reality, and empowering consumers to make smarter, more confident choices.Irina shares how the company's approach to personalization goes far beyond basic filters. It adapts to the user, the brand, the category, and even the shopping environment. And for retailers, Revieve delivers serious impact: boosting conversions, increasing basket size, and even informing product development through anonymized insights.If you're curious about the future of diagnostics in beauty, the role of AI in lifestyle-based skincare, or how trust and transparency are redefining the industry, this conversation is a must-listen. Tune in to discover how Revieve is building the infrastructure for the next generation of intelligent, ethical, and personalizedTo learn more about Revieve, visit their website and social media.CHAPTERS:(0:00) Introduction to Irina Mazur and Revieve(1:05) Irina's Career Journey and Tech Influence in Beauty(2:46) The Evolution of Beauty and Consumer Interactions(4:00) Revieve's Comprehensive Consumer Journey(5:58) The Real Meaning of Personalization in Beauty(9:03) Skin Analysis Through AI and Consumer Perception(12:04) Educating Consumers on Their Skin Health(14:01) How Revieve Guides Product Recommendations(25:53) Wellness Integration into Beauty and Future Expansion(29:12) Closing Thoughts on the Future of Personalization in BeautyPlease fill out this survey to give us feedback on the show!Don't forget to subscribe to Skin Anarchy on Apple Podcasts, Spotify, or your preferred platform.Reach out to us through email with any questions.Sign up for our newsletter!Shop all our episodes and products mentioned through our ShopMy Shelf! Hosted on Acast. See acast.com/privacy for more information.

The Weekly Blitz is brought to you by our friends over at Shop Marketing Pros. If you want to take your shop to the next level, you need great marketing. Shop Marketing Pros does top-tier marketing for top-tier shops. Click here to learn more about Top Tier Marketing by Shop Marketing Pros and schedule a demo: https://shopmarketingpros.com/chris/Check out their podcast here: https://autorepairmarketing.captivate.fm/If you would like to join their private facebook group go here: https://www.facebook.com/groups/autorepairmarketingmastermindVisit ShopMarketingPros.com/chris to partner with a team that understands your business. Because every great shop deserves marketing that's just as great. In episode six of "The Weekly Blitz," Coach Chris Cotton expertly guides auto repair shop owners through an in-depth, eight-step diagnostic process designed to improve shop consistency, profitability, and customer trust. Throughout the episode, he emphasizes the importance of clear communication with both technicians and customers, ensuring everyone understands the diagnostic procedures and findings. Chris highlights the necessity of thorough and accurate documentation at every stage, which not only protects the shop but also provides transparency for clients. He also stresses the value of charging appropriately for diagnostic work, explaining how this reinforces the professionalism of the shop and ensures technicians are compensated for their expertise.Chris delves into how implementing a standardized diagnostic approach helps prevent costly comebacks, reduces errors, and boosts technician confidence by providing a clear roadmap for every job. This consistency, he explains, leads to higher quality repairs and builds lasting, trust...

The Weekly Blitz is brought to you by our friends over at Shop Marketing Pros. If you want to take your shop to the next level, you need great marketing. Shop Marketing Pros does top-tier marketing for top-tier shops. Click here to learn more about Top Tier Marketing by Shop Marketing Pros and schedule a demo: https://shopmarketingpros.com/chris/Check out their podcast here: https://autorepairmarketing.captivate.fm/If you would like to join their private facebook group go here: https://www.facebook.com/groups/autorepairmarketingmastermindVisit ShopMarketingPros.com/chris to partner with a team that understands your business. Because every great shop deserves marketing that's just as great. In episode six of "The Weekly Blitz," Coach Chris Cotton expertly guides auto repair shop owners through an in-depth, eight-step diagnostic process designed to improve shop consistency, profitability, and customer trust. Throughout the episode, he emphasizes the importance of clear communication with both technicians and customers, ensuring everyone understands the diagnostic procedures and findings. Chris highlights the necessity of thorough and accurate documentation at every stage, which not only protects the shop but also provides transparency for clients. He also stresses the value of charging appropriately for diagnostic work, explaining how this reinforces the professionalism of the shop and ensures technicians are compensated for their expertise.Chris delves into how implementing a standardized diagnostic approach helps prevent costly comebacks, reduces errors, and boosts technician confidence by providing a clear roadmap for every job. This consistency, he explains, leads to higher quality repairs and builds lasting, trust...

In this expansive episode, Aneil Mallavarapu delivers a masterclass on what TechBio is really about and why most investors and founders are still getting it wrong. We dig into the communication gap between technical genius and venture capital, the brutal economics of research tools, the data dilemmas in wet AI, and why the future belongs to founders who can both build deep and speak simply.Aneil shares hard truths about platform strategy, revenue (yes, revenue), and the myth of “cool diagnostics” inside a broken healthcare system. But this isn't just about critique. It's a hopeful, strategic call for a new generation of purposeful companies, built not only for returns but for impact. If you're working at the intersection of biology, tech, and meaning, this is the one to listen to.

In this episode, Dr. Rachel welcomes Dr. Karen Davidson, a trailblazer in airway diagnostics and a disruptor in the world of nasal health. Dr. Karen takes us through her unconventional 34-year journey,from critical care flight nurse to patented inventor and airway educator,revealing how we've misunderstood nasal function for decades.Together, they unravel the science behind nasal resistance, debunk myths about CPAP therapy, and dive into why nasal function,not volume determines breathing quality. Dr. Karen shares how she pioneered the Daphne Score and the concept of pseudo-UARS, offering a data-driven approach to understanding airflow, pressure, and airway compensation.We also explore the systemic effects of nasal resistance,from heart rate variability in athletes to sleep-disordered breathing in children misdiagnosed with ADHD. With bold insights and a refreshing dose of cynicism, Dr. Karen challenges the current medical system and encourages collaboration across specialties to improve patient care.Highlights:Dr. Karen's journey from nurse to airway innovator and educatorWhy nasal function, not just nasal breathing mattersHow nasal resistance affects posture, speech, sleep, and heart rateThe creation and science behind the Daphne Score and airway AIUnderstanding pseudo-UARS and overexpansion risks in orthodonticsCPAP intolerance and why it often fails due to undiagnosed nasal resistanceThe flawed "disease management" model in healthcareWhy sleep doesn't disorder breathing, breathing disorders sleepNasal function as a key factor in ADHD misdiagnosis and childhood airway issuesFunctional diagnostics: From facial analysis to RhinoManometryThe neurological connection between nasal resistance and tongue functionThe importance of individualized treatment based on nasal flow and pressureThe emerging International Society of Airway Function Diagnostics & TherapeuticsAbout the Guest:Dr. Karen Fields-Lever is a critical care flight nurse, airway diagnostics expert, and creator of the patented Daphne Score software used to analyze nasal resistance and flow. With over 8,000 cases of ENT experience, she brings a rare blend of clinical and industry insight to breathing science. A published author and educator, Dr. Karen has pioneered flow-based orthodontics, Maverick nasal exams, and teaches across multiple specialties, including dentistry, ENT, chiropractic, and physical therapy. She is the founder of the International Society of Airway Function Diagnostics and Therapeutics, and her mission is clear: redefine how we measure, interpret, and treat the airway.Resources MentionedWebsite | karenparkerdavidson.comFounder of |International Society of Airway Function, Diagnostics, & TherapeuticsInstagram | @_thenoseknowsBooks MentioneDAmazon Link

On this episode of Longevity by Design, Dr. Gil Blander sits down with Dr. Karl Pfleger, aging biotechnology investor and creator of AgingBiotech.info, to dissect the rapidly evolving field of aging therapeutics. Karl breaks down the sector into two main categories: interventions that slow aging rates versus rejuvenation strategies that repair accumulated damage.Karl highlights the most promising areas in his investment portfolio, including senolytics for clearing senescent cells and epigenetic reprogramming technologies. He explains why current aging clocks aren't ready for clinical use and discusses the limitations of popular interventions like GLP-1 drugs and fasting protocols. The conversation reveals that 14 Phase 3 clinical trials are currently testing core aging therapeutics.The discussion covers recent FDA approvals for ATTR treatments and stem cell therapies, signaling the field's maturation. Karl emphasizes that meaningful life extension requires a "divide and conquer" strategy, targeting multiple aging mechanisms simultaneously rather than relying on single interventions. Despite exciting therapeutic developments, he maintains that optimizing diet, exercise, and sleep remains the most impactful strategy for extending healthspan today.Guest-at-a-Glance

In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, discuss summertime illnesses and key insights from a recent diagnostic investment event. Together, they explore:Common summertime illnesses, along with tips for prevention. How investment in diagnostic tools influences innovation in the laboratory.The potential impact of growing interest in AI investments. The investment interest in liquid biopsy and its potential implications for clinical decision-making.How AI development may accelerate adoption of mass spectrometry, proteomics, and similar advancements in clinical laboratories. 

Check out the TIES Sales Showdown at www.tx.ag/TIESVisit The Sales Lab at https://thesaleslab.org and check out all our guests' recommended readings at https://thesaleslab.org/reading-listTo listen to The Sales Lab Podcast on your favorite apps, visit https://thesaleslab.simplecast.com/ and select your preferred method of listening.Connect with us on Facebook at https://www.facebook.com/saleslabpodcastConnect with us on Linkedin at https://www.linkedin.com/company/thesaleslabSubscribe to The Sales Lab channel on YouTube at  https://www.youtube.com/channel/UCp703YWbD3-KO73NXUTBI-Q 

In today's VETgirl online veterinary continuing education podcast, Dr. Michelle Evason, BSc, DVM, DACVIM, MRCVS, Global Director of Veterinary Clinical Education at Antech, part of Mars Science & Diagnostics, discusses the cutting edge updates from the American College of Veterinary Internal Medicine (ACVIM) that you can't miss for your clinical day-to-day operations. Tune in to hear more about evidence based, head-to-head test comparisons!Sponsored By: Antech, MARS